DT388 GM-CSF

Drug Profile

DT388 GM-CSF

Alternative Names: DT-GM; Truncated diptheria toxin-granulocyte-macrophage colony-stimulating factor

Latest Information Update: 26 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medical University of South Carolina; National Cancer Institute (USA); Terry Fox Laboratory
  • Class Biological toxins; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Immunosuppressants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 26 Jul 2006 No development reported - Phase-I for Acute myeloid leukaemia in Canada (unspecified route)
  • 26 Jul 2006 No development reported - Phase-I for Acute myeloid leukaemia in USA (unspecified route)
  • 15 Oct 2001 A phase I study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top